The finalists for the biopharma track of INVEST Pitch Perfect have been selected. At the INVEST Pitch Perfect boutique healthcare investor conference, six biopharma companies will present their approaches to infectious disease, the track theme this year.

生物医药赛道的INVEST Pitch Perfect决赛入围者已选出。在INVEST Pitch Perfect精品医疗保健投资者会议上，六家生物医药公司将展示他们在传染病方面的方法，这是今年的赛道主题。

INVEST

投资

is scheduled for May 20-21 at the Willis Tower in Chicago. Investors serving as the biopharma track judges include: Ryan Kole, partner with V Capital; Matt Martin, Pathway Bioventures partner; and Michael Schultz, senior director of venture operations at Portal Innovation.

定于5月20日至21日在芝加哥的威利斯大厦举行。担任生物制药赛道评委的投资者包括：V Capital的合伙人瑞安·科尔；Pathway Bioventures的合伙人马特·马丁；以及Portal Innovation的风险运营高级总监迈克尔·舒尔茨。

To view the full agenda and register click here.

查看完整议程并注册，请点击这里。

Here is a preview of the biopharma track finalists presenting at INVEST Pitch Perfect.

以下是将在INVEST Pitch Perfect上展示的生物制药赛道决赛入围者的预览。

presented by

呈现者

Health Tech

健康科技

The 5 Best Software to Buy for Managing a Spa Franchise

管理水疗连锁店最值得购买的5款最佳软件

Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.

选择合适的软件可以直接改善客户管理、运营效率，并促进您的水疗连锁店的增长。了解哪种工具最适合您的业务。

By Meevo

由 Meevo 创作

Canurta Therapeutics

卡努尔塔治疗学

Antimicrobial resistance is an escalating global threat and a critical public health concern. Canurta has developed a library of hemp-derived molecules with anti-inflammatory and anti-microbial properties. Its research into virtual drug target interactions highlights the potential of cannflavins, a chemical compound derived from cannabis, to inhibit biofilm-related enzymes.

抗菌素耐药性是一个日益严重的全球威胁，也是公共卫生的关键问题。Canurta 开发了一个含有抗炎和抗菌特性的大麻衍生分子库。其关于虚拟药物靶点相互作用的研究强调了从大麻中提取的化学化合物——大麻黄酮抑制生物膜相关酶的潜力。

It suggests that cannflavins could be repurposed as antibacterial and antifungal agents against resistant microbial infections. The company has optimized cannflavin derivatives to enhance pharmacological profiles, focusing its R&D on identifying lead candidates by molecular docking and simulation, efficacy testing against drug-resistant microbes and evaluating synergies with other antimicrobials to eliminate drug-resistant bacteria and fungi, such as with non-azole antifungals in models of azole-resistant candidiasis..

它表明，cannflavins 可以被重新用作对抗耐药性微生物感染的抗菌和抗真菌剂。该公司优化了 cannflavin 衍生物以改善药理特性，集中研发工作于通过分子对接和模拟识别先导化合物、测试对耐药微生物的功效，以及评估与其他抗菌药物（如在唑类耐药念珠菌病模型中与非唑类抗真菌药）的协同作用，以消除耐药细菌和真菌。

Promedixinc

普罗米迪克斯公司

focuses on detecting sepsis at the early stages through noninvasive optical circulatory dysfunction monitoring. Sepsis is a leading cause of death in children and adults worldwide. Fast detection is key to survival. Early signs of sepsis include impaired peripheral circulation. A simple way to identify sepsis risk is capillary refill time (CRT).

专注于通过非侵入性光学循环功能障碍监测在早期阶段检测败血症。败血症是全球儿童和成人死亡的主要原因之一。快速检测是生存的关键。败血症的早期迹象包括外周循环受损。识别败血症风险的一种简单方法是毛细血管再充盈时间（CRT）。

ProMedix “PeriFRL” measures CRT for rapid, accurate and noninvasive diagnostics, as well as ongoing monitoring once a therapeutic intervention is underway at the patient’s bedside. After a nearly 600 patient observational study at Oregon Health & Sciences University Medical Center, PeriFRL was found to be as accurate as blood lactate in predicting sepsis. .

ProMedix “PeriFRL” 测量CRT，用于快速、准确且无创的诊断，以及在患者床边治疗干预开始后的持续监测。在俄勒冈健康与科学大学医学中心进行的近600例患者观察性研究后，发现PeriFRL在预测脓毒症方面与血液乳酸一样准确。

Sivec Biotechnologies, Inc

斯维奇生物技术公司

plans to become a global leader in delivering breakthrough, engineered biotherapeutics. Sivec has developed a first-in-class pipeline focused on cancer, genetic, and respiratory diseases using their next-generation intracellular biologic drug delivery platform. BactPac is a solution for all-in-one therapeutic payload production and targeted delivery.

计划成为提供突破性工程化生物治疗药物的全球领导者。Sivec 已开发出一个首创的管道，专注于利用其下一代细胞内生物药物递送平台治疗癌症、遗传和呼吸系统疾病。BactPac 是一个集治疗载荷生产与靶向递送于一体的解决方案。

It is engineered to produce and safely deliver large and structured therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas) to targeted tissues and tumors. It evades immune recognition and neutralizes antibodies, enabling repeat dosing to tissues and tumors inaccessible to other drug delivery systems. .

它被设计用于生产和安全地将大型和结构化的治疗载荷（mRNA、siRNA、蛋白质/纳米抗体以及CRISPR/Cas）递送到目标组织和肿瘤。它能够逃避免疫识别并中和抗体，从而实现对其他药物递送系统无法到达的组织和肿瘤进行重复给药。

Taxis Pharmaceuticals Inc

出租车制药公司

is a clinical-stage company developing drug candidates that enable the re-use of the most widely prescribed generic antibiotics against antibiotic-resistant bacterial infections. Its most advanced drug candidate, TXA709, is currently enrolling participants in a Phase I human clinical trial as an oral anti-MRSA therapeutic..

是一家临床阶段的公司，正在开发可重新使用最广泛处方的通用抗生素对抗抗生素耐药菌感染的候选药物。其最先进的候选药物TXA709目前正在招募第一阶段人体临床试验的参与者，作为口服抗MRSA治疗药物。

presented by

呈现者

Sponsored Post

赞助帖子

How to Improve Employee Benefits While Reducing Insurance Costs

如何在降低保险成本的同时提高员工福利

Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.

平衡医疗福利和保险成本需要研究。从成为差异卡会员到提供健康资源，有许多方法可以以低成本改善医疗保健。

By The Difference Card

通过差异卡

ClearSight Therapeutics,

清视疗法，

Inc is focused on treating acute infectious conjunctivitis.  ClearSight is developing the first over-the-counter eye drops to treat all forms of acute infectious conjunctivitis, commonly known as “pink eye.” Each year, pink eye impacts up to 6 million children and adults in the United States, leading to nearly $2 billion in lost wages as children are kept home from school and parents miss work.

Inc专注于治疗急性传染性结膜炎。ClearSight正在开发首个非处方眼药水，用于治疗所有形式的急性传染性结膜炎，通常称为“红眼病”。每年，红眼病影响美国多达600万儿童和成人，导致近20亿美元的工资损失，因为孩子留在家中不上学，父母也因照顾孩子而缺勤。

Current treatments consist of prescription antibiotics, which are only effective for 20% of bacterial cases; up to 80% of infections are viral..

目前的治疗方法包括处方抗生素，但其仅对 20% 的细菌感染病例有效；高达 80% 的感染是由病毒引起的。

Yaso Therapeutics

亚索治疗学

is a clinical-stage pharmaceutical company developing anti-infective drug products as well as a contraceptive. Its mission is to develop cutting-edge treatment and prevention products based on a broadly acting polyanion with a core effort focused on women’s health.

是一家临床阶段的制药公司，正在开发抗感染药物产品以及避孕药。其使命是基于广泛作用的聚阴离子开发前沿的治疗和预防产品，核心工作集中在女性健康上。

Photo:

照片：

Osaka Wayne Studios, Getty Images

大阪韦恩工作室，盖蒂图片社